Dasatinib Drug Profile | PharmaGraphX

Clinical alerts

Bleeding risk

Additive with other antithrombotics and NSAIDs

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Hepatotoxic

Monitor liver function

Mechanism of action

Inhibits BCR-ABL (including T315I-mutant), SRC family, c-KIT, EPHA2, PDGFR

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
·Chronic Phase Chronic Myeloid Leukemia
·Chronic Myeloid Leukemia, Chronic Phase
·Advanced Lymphoma
·Advanced Malignant Solid Neoplasm

Interactions

No curated interaction pairs are recorded for Dasatinib. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Myelosuppression
Fluid retention
Diarrhea
Headache
Pleural effusion

Food, alcohol & herbal

Food

Avoid antacids, H2 blockers, PPIs — require acid for absorption

Alcohol · moderate

Additive hepatotoxicity

Herbal

St. John's Wort (major) — Reduces dasatinib levels

Pharmacokinetics

Half-life: 3-5 hours
Protein binding: 96%
Metabolised by: CYP3A4

Pregnancy & lactation

Not recorded for Dasatinib. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.